FDA to review supplemental New Drug Application for mepolizumab for treatment of nasal polyps

The submission is based on data from the SYNAPSE study (n>400) which met both co-primary endpoints when added to standard of care, with statistically significant improvements in both the size of nasal polyps at week 52 and in nasal obstruction during weeks 49-52.

Source:

PharmaTimes